

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

(use as many sheets as necessary)

PTO/SB/08B (08-03)

Approved for use through 07/31/2008, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	10/769,565
Filing Date	January 29, 2004
First Named Inventor	Mary NG Mah Lee
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	59419-010102

Sheet	1	of	4
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]


LA-FS1\317756v01\59419.010102

Examiner Signature	<i>M. M. [Signature]</i>	Date Considered	07/08/06
-----------------------	--------------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/RFO.		Complete if Known	
		Application Number	10/769,565
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	January 29, 2004
		First Named Inventor	Mary NG Mah Lee
		Art Unit	1614
		Examiner Name	To be assigned
		Attorney Docket Number	59419-010102
Sheet	2	of	4


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MRS		Adlish <i>et al.</i> ; Identification of a putative cell receptor for human cytomegalovirus; Virology; 1990; Vol. 176; pp. 337-345.	
		Agnello <i>et al.</i> ; Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor, Proc Natl Acad Sci; Oct 26, 1996; Vol. 96, No. 22; pp. 12766-12771.	
		Atkinson <i>et al.</i> ; Purification and properties of HeLa cell plasma membranes; J Biol Chem; August 25, 1971; Vol. 246, No. 16; pp. 5162-5175.	
		Beasley <i>et al.</i> ; Identification of neutralizing epitopes within structural domain III of the West Nile virus envelop protein; J. Virol.; Dec 2002; Vol. 76, No. 24, pp. 13097-13100.	
		Bielefeldt-Ohmann <i>et al.</i> ; Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains; Virus Res.; 2001; Vol. 73; pp. 81-89.	
		Blau <i>et al.</i> ; Entry and release of measles virus are polarized in epithelial cells; Virology; 1995; Vol. 210; pp. 91-99.	
		Borrow <i>et al.</i> ; Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus; J Virol.; Dec 1992; Vol. 66, No. 12; pp. 7270-7281.	
		Bruett <i>et al.</i> ; Characterization of a membrane-associated protein implicated in visna virus binding and infection; Virology; 2000; Vol. 271; pp. 132-141.	
		Cao <i>et al.</i> ; Identification of α -Dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus; Science; Dec 11, 1998; Vol. 282; pp. 2079-2081.	
		Castle <i>et al.</i> ; Primary structure of the West Nile flavivirus genome region coding for all nonstructural proteins. Virology; 1986; Vol. 149; pp. 10-26.	
		Castle <i>et al.</i> ; Sequence analysis of the viral core protein and the membrane-associated proteins VI and NV2 of the flavivirus West Nile virus and of the genome sequence for these proteins; Virology; 1985; Vol. 145; pp. 227-236.	
M/P		Chen <i>et al.</i> ; Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate; Nat Med; Aug. 1997; Vol. 139, No. 8; pp. 239-251.	

LA-FS1317756v01/59419.010102	
Examiner Signature	Date Considered
<i>M. P. Lee</i>	07/05/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 10/769,565		Complete if Known	
		Application Number	10/769,565
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	January 29, 2004
		First Named Inventor	Mary NG Mah Lee
		Art Unit	1614
		Examiner Name	To be assigned
		Attorney Docket Number	59419-010102
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
mfs		Choi <i>et al.</i> ; Reovirus binds to multiple plasma membrane proteins of mouse L fibroblasts; Virology; 1990; Vol. 178; pp. 316-320.	
		Chu <i>et al.</i> ; Infection of polarized epithelial cells with flavivirus West Nile: Polarized entry and egress of virus occur through apical surface; J Gen Virol.; 2002; Vol. 83; pp. 2427-2435.	
		Chu <i>et al.</i> ; Trafficking mechanism of West Nile (Sarafend) virus structural proteins; J Med Virol.; 2002; Vol. 67; pp. 127-136.	
		Cote <i>et al.</i> ; Generation of human monoclonal antibodies reactive with cellular antigens; Proc. Natl. Acad. Sci. USA; April 1983; Vol. 80; pp. 2026-2030.	
		Crane <i>et al.</i> ; Identification of cell membrane proteins that bind visna virus; J Virol.; Nov 1991; Vol. 65, No. 11; pp. 6137-6143.	
		Crill <i>et al.</i> ; Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells; J Virol.; Aug 2001; Vol. 75, No. 16; pp. 7769-7773.	
		Hasegawa <i>et al.</i> ; Mutations in the envelope protein of Japanese encephalitis virus affect entry into cultured cells and virulence in mice; Virology; 1992; Vol. 191; pp. 158-165.	
		Helenius; Alphavirus and flavivirus glycoproteins: structures and functions; Cell; June 2, 1995; Vol. 81; pp. 651-653.	
		Kimura <i>et al.</i> ; Analysis of virus-cell binding characteristics on the determination of Japanese encephalitis virus susceptibility; Arch Virol; 1994; Vol. 139; pp. 239-251.	
		Lee <i>et al.</i> ; Substitutions at the Putative Receptor-Binding Site of an Encephalitic Flavivirus Alter Virulence and Host Cell Tropism and Reveal for Glycosaminoglycans in Entry; J. of Virology; Oct. 2000; Vol. 74, No. 19; pp. 8867-8875.	
		Martinez-Barragan <i>et al.</i> ; Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection; J Virol.; Sep 2001; Vol. 75, No. 17; pp. 7818-7827.	
		Ng <i>et al.</i> ; Possible involvement of receptors in the entry of Kunjin virus into Vero cells; Arch Virol.; 1988; Vol. 100; pp. 199-211.	
mfs		Ng <i>et al.</i> ; Transport and budding at two distinct sites of visible nucleocapsids of West Nile (Sarafend) virus; J Med Virol.; 2001; Vol. 65; pp. 758-764.	


LA-FS1\317756v01\59419.010102

Examiner Signature	<i>M. NG Mah Lee</i>	Date Considered	07/05/06
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/769,565		
		Filing Date	January 29, 2004		
		First Named Inventor	Mary NG Mah Lee		
		Art Unit	1614		
		Examiner Name	To be assigned		
Sheet	4	of	4	Attorney Docket Number	59419-010102

NON PATENT LITERATURE DOCUMENTS			
MFS		Putnak <i>et al.</i> ; A putative cellular receptor for dengue viruses; Nat Med.; Aug 1997; Vol. 3, No. 8; pp. 828-829.	
		Rappole <i>et al.</i> ; Migratory birds and spread of West Nile virus in the Western Hemisphere; Emerg Infect Dis; July-Aug 2000; Vol. 6, No. 4; pp. 319-328.	
		Sagara <i>et al.</i> ; 71-kilodalton heat shock cognate protein acts as a cellular receptor for syncytium formation induced by human Tcell lymphotropic virus type 1; J Virol; Jan 1998; Vol. 72, No. 1; pp. 535-541.	
		Salas-Benito <i>et al.</i> ; Identification of two surface proteins from C6/36 cells that bind dengue type 4 virus; J Virol; Oct 1997; Vol. 71, No. 10; pp. 7246-7252.	
		Schneider-Schaulies; Cellular receptors for viruses: links to tropism and pathogenesis; J Gen Virol; 2000; Vol. 81, pp. 1413-1429.	
		Se-Thoe <i>et al.</i> ; Alteration of virus entry mode: a neutralization mechanism for Dengue-2 virus; J Med Virol; 2000; Vol. 62, pp. 364-376.	
		Taylor <i>et al.</i> ; The human cytomegalovirus receptor on fibroblasts is a 30-kilodalton membrane protein; J Virol; June 1990; Vol. 64, No. 6; pp. 2484-2490.	
		Thullier <i>et al.</i> ; Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism; J Gen Virol; 2001; Vol. 82, pp. 1885-1892.	
MFS		Verdin <i>et al.</i> ; Characterization of a common high-affinity receptor for reovirus serotypes 1 and 3 on endothelial cells; J Virol; Mar 1989; Vol. 63, No. 3; pp. 1318-1325.	


LA-FS1317756v01\59419.010102

Examiner Signature		Date Considered	07/07/06
-----------------------	--	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/769,565
Filing Date	January 29, 2004
First Named Inventor	Mary NG Mah Lee
Art Unit	1614
Examiner Name	To be assigned
Attorney Docket Number	59419-010102

Sheet	1	of	2
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MKS		Castle <i>et al</i> ; Nucleotide sequence of the 5'-terminal untranslated part of the genome of the flavivirus West Nile virus; Arch Virol; Vol. 92; 1987; pp. 309-313.	
		Cole <i>et al</i> ; The EBV-Hybridoma Technique and Its Application to Human Lung Cancer; Monoclonal Antibodies And Cancer Therapy; Alen R. Liss, Inc.; 1985; pp. 77-96	
		Cote <i>et al</i> ; Generation of human monoclonal antibodies reactive with cellular antigens; Proc. Natl Acad. Sci. USA; Vol. 80; April 1983; pp. 2026-2030.	
		De Madrid <i>et al</i> ; The flaviviruses (group B arboviruses): a cross-neutralization study; J Gen Virol; Vol. 23; 1974; pp. 91-96.	
		George <i>et al</i> ; Isolation of West Nile virus from the brains of children who had died of encephalitis; Bull World Health Organ; Vol. 62, No. 6; 1984; pp. 879-882.	
		Gollins <i>et al</i> ; Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry; J Gen Virol; Vol. 66; 1985; pp. 1969-1982.	
		Hase <i>et al</i> ; A comparative study of entry modes into C 6/36 cells by Semliki Forest and Japanese encephalitis viruses; Archives of Virology; Vol. 108; 1989; pp. 101-114	
		Hase <i>et al</i> ; Entry and replication of Japanese encephalitis virus in cultured neurogenic cells; J Virol Methods; Vol. 30; 1990; pp. 205-214.	
		Hase <i>et al</i> ; Flavivirus entry into cultured mosquito cells and human peripheral blood monocytes; Arch Virol; Vol. 104; 1989; pp. 129-143.	
		Hase <i>et al</i> ; Morphogenesis of flaviviruses; Subcell Biochem; Vol. 15; 1989; pp. 275-305.	
		Heinz <i>et al</i> ; The interactions of the flavivirus envelope proteins: implications for virus entry and release; Arch Virol Suppl; Vol. 9, Suppl; 1994; pp. 339-348.	
		Köhler <i>et al</i> ; Continuous cultures of fused cells secreting antibody of predefined specificity; Nature; Vol. 256; Aug 7, 1975; pp. 495-497.	
		Kopecký <i>et al</i> ; A putative host cell receptor for tick-borne encephalitis virus identified by anti-idiotypic antibodies and virus affinoblotting; Intervirology; Vol. 42; 1999; pp. 9-16.	
MKS		Kozbor <i>et al</i> ; The production of monoclonal antibodies from human lymphocytes; Immunology Today; 1983; Vol. 4, No. 3; pp. 72-79.	

LA-FS1321389v01\59419.010102

Examiner Signature		Date Considered	07/05/06
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/769,565
		Filing Date	January 29, 2004
		First Named Inventor	Mary NG Mah Lee
		Art Unit	1614
		Examiner Name	To be assigned
		Attorney Docket Number	59419-010102
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
MPS		Ramos-Castaneda <i>et al</i> ; A 65-kDa trypsin-sensible membrane cell protein as a possible receptor for dengue virus in cultured neuroblastoma cells; J Neurovirol; Vol. 3; 1997; pp. 435-440.	
		Rey <i>et al</i> ; The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution; Nature; Vol. 375; May 25, 1995; pp. 291-298.	
		Rice; <i>Flaviviridae</i> : the viruses and their replication; Fields Virology, Third Edition; Fields, <i>et al</i> editors; Lippincott-Raven; Philadelphia, PA.; Chapter 30; pp. 931-959.	
		Shi <i>et al</i> ; Actions of neurotensin: a review of the electrophysiological studies; Ann NY Acad. Sci.; Vol. 668; 1992; 1129-145.	
		Tokuyasu; Immuno-cryoultramicrotomy; Immunolabelling for Electron Microscopy; Polak <i>et al</i> . editors; Amsterdam; Elsevier Science; Chapter 6; pp. 71-82.	
		Wengler <i>et al</i> ; Sequence analysis of the membrane protein V3 of the flavivirus West Nile virus and of its gene; Virology; Vol. 147; 1985; pp. 264-274.	
MPS		Wengler <i>et al</i> ; Studies on virus-specific nucleic acids synthesized in vertebrate and mosquito cells infected with flaviviruses; Virology; Vol. 89; 1978; pp. 423-437.	

LA-FSI\321389v01\59419.010102

Examiner Signature		Date Considered	07/15/04
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. †† Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ‡‡ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.